David Carbone, M.D., Ph.D.
- Contact Address
- Vanderbilt-Ingram Cancer Center
685 Preston Building
Nashville, TN, 372326838 - Contact Phone
- (615) 936-1279
- Professional Affiliations
- Vanderbilt-Ingram Cancer Center
Position held: Harold L. Moses Chair in Cancer Research - Vanderbilt-Ingram Cancer Center
Position held: Ingram Professor of Cancer Research - Vanderbilt-Ingram Cancer Center
Position held: Director of Specialized Program of Research Excellence in Lung Cancer - Vanderbilt-Ingram Cancer Center
Position held: Director of the Experimental Therapeutics Program
- Vanderbilt-Ingram Cancer Center
- Expertise
- Non-Small Cell Lung Cancer
- Small Cell Lung Cancer
- Mesothelioma
- Thymoma and Thymic Carcinoma
- Education
- Johns Hopkins University, M.D.,
- Johns Hopkins University, Molecular Biology and Genetics, Ph.D.,
- Residencies
- Internship and Residency, The Johns Hopkins Hospital, Internal Medicine,
- Fellowships
- National Cancer Institute, Medical Oncology,
- Website
- Biography/CV (will open new window)
- Biography
David Carbone graduated summa cum laude from Amherst College in 1977 and received an MD and a PhD in Molecular Biology and Genetics at Johns Hopkins University in 1985. He then did an Internal Medicine internship and residency at The Johns Hopkins Hospital through 1988 followed by a Medical Oncology fellowship at the National Cancer Institute in Bethesda, MD. In 1991 he was appointed Assistant Professor at the University of Texas Southwestern Medical Center and was promoted to Associate Professor with tenure in 1995. He was recruited to Vanderbilt University in 1996 where he was promoted to full Professor in 1998.
He is currently Professor of Medicine and Cancer Biology at the Vanderbilt University Medical Center and Director of the Experimental Therapeutics Program at the Vanderbilt-Ingram Cancer Center. He is also Director and Principal Investigator of the Vanderbilt Specialized Program of Research Excellence (SPORE) in Lung Cancer. His research interests, grant support and publications have been focused on lung cancer, and specifically lung cancer genetics, cancer immunotherapy, tumor-associated immunosuppression mechanisms and gene therapy. Recent research directions include molecular profiling of lung cancers and preneoplasias, especially the use of mass spectrometry-based proteomics. He as over 100 peer-reviewed publications and review articles, has served on several NCI grant review panels, and has continuous NCI funding since early in his career. He has served on organizing committees for both ASCO and AACR and is currently Chair of the Lung Biology subcommittee for the Eastern Cooperative Oncology Group and currently serves on the Board of Scientific Counselors for the NCI.
